Title: Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway
Author Manuscript Published OnlineFirst on May 13, 2020; DOI: 10.1158/1535-7163.MCT-19-1172 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 TITLE PAGE 2 Title: Autocrine CCL5 effect mediates trastuzumab resistance by ERK pathway 3 activation in HER2-positive breast cancer 4 Authors: Sandra Zazo1, Paula González-Alonso1, Ester Martín-Aparicio1, Cristina 5 Chamizo1, Melani Luque1, Marta Sanz-Álvarez1, Pablo Mínguez2, Gonzalo Gómez- 6 López3, Ion Cristóbal4, Cristina Caramés4, Jesús García-Foncillas4, Pilar Eroles5, Ana 7 Lluch5,6, Oriol Arpí7, Ana Rovira7,8, Joan Albanell7,8,9, Juan Madoz-Gúrpide1§, Federico 8 Rojo1§ 9 Affiliations: 1Pathology, Fundación Jiménez Díaz University Hospital Health Research 10 Institute (IIS—FJD, UAM)—CIBERONC, Madrid 28040, Spain; 2Genetics 11 Department, Health Research Institute-Fundación Jiménez Díaz (IIS-FJD, UAM), 12 Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid 13 28040, Spain; 3Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), 14 Madrid 28029, Spain; 4Translational Oncology Division, OncoHealth Institute, Health 15 Research Institute-Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid 28040, Spain; 16 5Institute of Health Research INCLIVA-CIBERONC, Valencia 46010, Spain; 17 6Medicine Department, University of Valencia, Valencia 46010, Spain; 7Cancer 18 Research Program, IMIM (Hospital del Mar Research Institute), Barcelona 08003, 19 Spain; 8Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona 20 08003, Spain; 9Universitat Pompeu Fabra, Barcelona 08002, Spain; §these authors 21 contributed equally to this work. 22 Running title: Trastuzumab resistance by CCL5/ERK axis activation 23 Keywords: breast cancer, HER2-positive, anti-receptor therapy, trastuzumab, 24 resistance, cytokines, CCL5, cell lines 1 Downloaded from mct.aacrjournals.org on October 2, 2021.
[Show full text]